Just 1 in 5 dollars spent on 15 top-selling “partial orphan drugs” – those approved to treat both rare and common diseases – were for the rare diseases for which the sponsors of these drugs received lucrative orphan drug benefits.
Among privately and publicly insured patients aged 13-64 years undergoing dental procedures between 2013-2018, two-thirds of opioid prescriptions were for tooth extraction, a procedure for which opioids are no better than over-the-counter pain medications such as ibuprofen.
Among Medicare Advantage enrollees hospitalized for influenza in 2018, mean out-of-pocket spending was almost $1,000, suggesting that cost-sharing for COVID-19 hospitalizations may be substantial in this population if voluntary waivers of cost-sharing from insurers are allowed to expire.
Latest research from CHEAR Faculty Dr. Jeremy Adler
Dr. Chua and collaborators conducted an online survey of 1,193 parents of school-aged children in Illinois, Michigan, and Ohio to assess their plans for sending children to school during the 2020-2021 school year and to assess their views on 15 potential measures that might be implemented to reduce COVID-19 risk in schools.
In this Health Affairs blog post, Dr. Chua highlights the fact that many orphan drugs approved to treat rare diseases are either currently being used to treat COVID-19 patients off-label and/or are currently in COVID-19 clinical trials. Because orphan drug policy facilitates high prices, Dr. Chua argues that this policy unintentionally could impede access to potentially life-saving treatments for COVID-19.
In this month's issue of Science Magazine, CHEAR director and President of the Society for Medical Decision Making, Dr. Lisa A. Prosser is among the many directors co-signing an open letter urging scientists around the world to rapidly and openly share their COVID-19 modeling and research pertinent to the on-going pandemic and its consequences for health and society.
In a new Health Affairs blog post and Detroit Free Press op-ed piece, Dr. Kao-Ping Chua reviews the scenarios under which COVID-19 evaluation is and is not free, and argues that federal legislation is needed to completely eliminate patient financial liability for COVID-19 evaluation, regardless of the nature of that evaluation.  
In a new JAMA Pediatrics Viewpoint, CHEAR Faculty Investigator Dr. Kao-Ping Chua and colleagues review early evidence suggesting that opioid prescribing limits have only had modest effects on opioid prescribing, highlight potential reasons for these disappointing results, and argue that a strategy relying on opioid prescribing limits alone is unlikely to substantially reduce excessive opioid prescribing.